BDSX Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
26.9M
+5.1%
25.6M
-11.1%
28.8M
+32.1%
21.8M
+8.7%
20.0M
Cost of Revenue
4.8M
+14.6%
4.2M
-13.8%
4.9M
+18.8%
4.1M
+1.9%
4.0M
Gross Profit
22.0M
+3.2%
21.4M
-10.6%
23.9M
+35.2%
17.7M
+10.5%
16.0M
Operating Expenses
27.4M
-0.4%
27.6M
+6.6%
25.8M
+4.6%
24.7M
-3.9%
25.7M
R&D
3.1M
-4.6%
3.3M
+14.5%
2.9M
-4.1%
3.0M
-8.5%
3.3M
SG&A
24.3M
+0.1%
24.3M
+5.6%
23.0M
+5.8%
21.7M
-3.1%
22.4M
Operating Income
-5388000
+13.1%
-6201000
-215.3%
-1967000
+72.1%
-7051000
+27.5%
-9719000
EBITDA
-3989000
+16.9%
-4800000
-729.0%
-579000
+89.7%
-5637000
+31.7%
-8257000
Net Income
-7273000
+6.7%
-7793000
-95.8%
-3980000
+54.3%
-8716000
+24.0%
-11468000
EPS (Basic)
$-0.71
+12.3%
$-0.81
-65.3%
$-0.49
+57.8%
$-1.16
+25.6%
$-1.56
EPS (Diluted)
$-0.71
+12.3%
$-0.81
-65.3%
$-0.49
+57.8%
$-1.16
+25.6%
$-1.56
Shares (Diluted)
10.3M
+6.6%
9.7M
+19.6%
8.1M
+7.6%
7.5M
+2.3%
7.3M
Biodesix (BDSX) โ€” Financials